Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMERALD-3: Durvalumab + Tremelimumab ± Lenvatinib with TACE vs TACE Alone in Locoregional HCC
2023-508701-24-00Phase 3Authorised
- Sponsor
- AstraZeneca
- Start
- Apr 2024
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 21
01
Overview
Phase 3, randomised, open-label trial of durvalumab, tiragolumab and lenvatinib in hepatocellular carcinoma (HCC) (3 arms), sponsored by AstraZeneca. Primary endpoint: Progression-free survival. Planned start Apr 2024; status: authorised.
02
Drugs
durvalumabtiragolumablenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2023-508701-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508701-24-00.